bluebird bio

bluebird bio is a biotechnology company based in Somerville, Massachusetts, specializing in gene therapies for severe genetic disorders and cancers. Founded in 1992 as Genetix Pharmaceuticals, the company rebranded in 2010 and has since grown to over 800 employees worldwide. bluebird bio is committed to developing one-time gene therapies that provide long-term solutions for patients with limited treatment options. The company’s key offerings include Lentiglobin™, a therapy for beta-thalassemia and sickle cell disease, and CAR T-cell therapies for various cancers, including multiple myeloma. bluebird bio employs lentiviral vector-based gene delivery to insert functional genes into patients' hematopoietic stem cells, aiming for durable therapeutic effects. Their investigational therapies also target conditions like cerebral adrenoleukodystrophy (CALD). bluebird bio collaborates with academic institutions, healthcare providers, and regulatory bodies to enhance patient access to its innovative therapies, which are designed as single-dose treatments to reduce the treatment burden. The company continues to focus on advancing its pipeline and ensuring global accessibility to its gene therapies.